

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Tuberculosis	Not applicable	<p>Mouse studies suggest Gleevec imatinib could help treat <i>Mycobacterium tuberculosis</i> infection. In mice infected with <i>M. tuberculosis</i>, Gleevec decreased bacterial load in the lung and spleen compared with vehicle ($p=0.001$). In mice infected with rifampicin-resistant <i>M. marinum</i>, the drug decreased bacterial load in the spleen compared with media ($p=0.0004$). Next steps include a clinical trial.</p> <p>Gleevec, an inhibitor of multiple kinases including the oncogenic fusion protein BCR-ABL tyrosine kinase, is marketed by Novartis AG to treat multiple cancers.</p> <p>SciBX 4(47); doi:10.1038/scibx.2011.1331 Published online Dec. 8, 2011</p>	<p>Patented; aspects available for licensing from Emory University Contact: Cory Acuff, Emory University, Atlanta, Ga. e-mail: cacuff@emory.edu</p>	<p>Napier, R.J. <i>et al. Cell Host Microbe</i>; published online Nov. 17, 2011; doi:10.1016/j.chom.2011.09.010 Contact: Daniel Kalman, Emory University School of Medicine, Atlanta, Ga. e-mail: dkalman@emory.edu</p>